Adial Pharmaceuticals, Inc. (ADIL)
NCM · Healthcare · Biotechnology
$2.98
+0.00%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$6.5M
Shares Outstanding
2.2M
Exchange
NCM
Currency
USD
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -1.9M | -1.8M | -1.9M | -2.0M |
| Net Income | -2.0M | -1.8M | -2.0M | -2.0M |
| Diluted EPS | $-4.50 | $-2.00 | $nan | $-1.48 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -10.9M | -6.9M | -8.3M | -7.8M |
| Net Income | -12.7M | -5.1M | -13.2M | -8.0M |
| Diluted EPS | $-317.75 | $-90.00 | $-68.01 | $-11.93 |